Prof. Dr. David Stejskal | Nanobiotechnology | Best Researcher Award
Professor, MD, PhD, MBA, EuSpLM, Head of the Institute of Laboratory Medicine | University Hospital in Ostrava | Czech Republic
Prof. Dr. David Stejskal, MD, PhD, MBA, EuSpLM, is a distinguished researcher and academic leader in the field of laboratory medicine, clinical biochemistry, and internal medicine. His research primarily focuses on the identification and clinical validation of novel biomarkers relevant to metabolic, cardiovascular, nephrological, and inflammatory diseases. With over 3,767 citations, an h-index of 29 (Scopus), and more than 200 peer-reviewed publications, his scholarly influence spans translational diagnostics and clinical applications in metabolic and endocrine disorders. His most cited works include pioneering studies on fatty acid binding proteins (FABP), chemerin, and FGF23, which have significantly advanced understanding of biomarkers in metabolic syndrome, chronic kidney disease, and cardiovascular risk assessment. Prof. Dr. David Stejskal’s research group has also contributed substantially to the development of novel diagnostic markers for diabetes, obesity, and atherosclerosis, as well as the evaluation of inflammatory and oxidative stress parameters in internal medicine. Beyond journal publications, he has authored and co-authored several scientific books such as Metabolic Diseases of Mass Incidence, Dyslipidemia, and Urolithiasis, alongside chapters in specialized medical encyclopedias. His work has been instrumental in shaping biomarker-based diagnostic strategies across Central Europe. Prof. Dr. David Stejskal has received notable research and organizational recognitions, including the OMICS Award (USA) for excellence in translational medicine and the Czech Society of Clinical Biochemistry Award. As an editorial contributor, reviewer, and conference organizer, he has significantly influenced international collaboration in laboratory and clinical research. His continued focus on biochemical innovation, diagnostic optimization, and translational research highlights his contribution to advancing laboratory medicine and evidence-based clinical diagnostics globally.
Profiles: Scopus | ORCID | ResearchGate | Sci Profiles | Web of Science
Featured Publications
1. Sigutova, R., Evin, L., Kusnierova, P., Svagera, Z., Branny, M., & Vaclavik, J. (2025). Specific microRNAs for heart failure: Reference values in whole blood. Biomedicines, 13(10), 2559. https://doi.org/10.3390/biomedicines13102559
2. Urinovska, R., Sistik, P., Buzga, M., & Stejskal, D. (2024). Fast and easy simultaneous determination of riboflavin, folic acid, all-trans-retinol and α-tocopherol in human serum by LC/MS/MS for bariatric patients. Journal of Chromatographic Science. https://doi.org/10.1093/chromsci/bmae035
3. Johannsen, B., Baumgartner, D., Karpíšek, M., Paust, N., Zengerle, R., & Mitsakakis, K. (2024). Integration of a bead-based immunoassay on a commercial PCR-performing POC device. Proceedings, 2024(097166). https://doi.org/10.3390/proceedings2024097166
4. Johannsen, B., Baumgartner, D., Karpíšek, M., Paust, N., Zengerle, R., & Mitsakakis, K. (2023). Patient stratification for antibiotic prescriptions based on the bound-free phase detection immunoassay of C-reactive protein in serum samples. Biosensors, 13(12), 1009. https://doi.org/10.3390/bios13121009
5. Plášek, J., Lazárová, M., Dodulík, J., Švagera, Z., Všianský, F., & Václavík, J. (2022). Secretoneurin as a novel biomarker of cardiovascular episodes: Are we there yet? A narrative review. Journal of Clinical Medicine, 11(23), 7191. https://doi.org/10.3390/jcm11237191